Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
Under what circumstances would you use pasireotide in the management of insulinoma-associated hypoglycemia?
Vega-Beyhart, et al., PMID 40165498
Related Questions
How does your hospital approach the use of insulin pumps for admitted patients?
Should long-acting subcutaneous insulin be started upfront in addition to regular insulin infusion for patients with diabetic ketoacidosis?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
Is it safe to use acarbose in patients with advanced chronic kidney disease?
Do you recommend switching from a GLP-1 agonist to insulin in female patients with type 2 diabetes who are planning to become pregnant?
When do you recommend screening patients with T2DM for heart failure?
Would you start once-weekly tirzepatide over once daily basal insulin in a patient with Type 2 diabetes with inadequate control on oral antihyperglycemia drugs?
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Under what circumstances would you prioritize injectable semaglutide over oral semaglutide in patients with type 2 diabetes with atherosclerotic cardiovascular disease or chronic kidney disease?
Would you recommend the use of an ACE inhibitor to patients with Type 1 diabetes mellitus who are normotensive but have persistent moderate proteinuria?